Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Myriad Genetics initiates Phase II trial of Azixa in lung cancer
The company’s two previously announced Phase II trials are studying primary brain cancer and melanoma that has spread to the brain. This third Phase II trial is designed
The company’s two previously announced Phase II trials are studying primary brain cancer and melanoma that has spread to the brain. This third Phase II trial is designed
Carrington says the toxicology studies are a critical step during the vaccine development and will assess the vaccine safety in animals. Pending successful results of the toxicology studies
The clinical trial is designed to evaluate the effectiveness and safety of Alinia tablets administered in combination with Pegasys and Copegus in 60 patients with chronic hepatitis C
Under the terms of the agreement, Millipore will have exclusive worldwide rights to market and sell Novo Nordisk’s recombinant human insulin, branded by Millipore as Incelligent SG and
CoFactor is a folate-based biomodulator drug designed to enhance the activity and reduce associated toxicity of the cancer chemotherapeutic agent 5-FU. It is currently being investigated in a
CTI will be responsible for marketing, sales, and development of the drug in the US, while the drug will continue to be sold outside the US by Bayer
The agreement grants Gilead worldwide commercialization rights to P-680 for the treatment of diseases including cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and non-CF bronchiectasis. In addition,
Millemmium says the trial, named Evolution, will combine Velcade with lenalidomide/ dexamethasone and also explore the incremental benefit of cyclophosphamide, an alkylating agent, which in previous studies has
The study achieved statistical significance on the primary endpoint. Results across the 12 weeks of treatment showed both statistically significant and clinically relevant outcomes for patients with breakthrough
The FDA indicated that it will provide a revised timeline to Endo and Vernalis, and the companies will make an announcement when appropriate. Until the companies receive further